Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee

FDA's Pediatric Advisory Committee recommends continued monitoring for an additional year of pediatric adverse events associated with Novartis' anti-hypertensive Lotensin